PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATION AND PAIN
The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a methanesulfonylalkylnitrile compound, or a pharmaceutically acceptable salt or solvate thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering a methanesulfonylalkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
1 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and 5-methanesulfonylpentanenitrile or 7-methanesulfonylheptanenitrile, or a pharmaceutically acceptable solvate thereof.
2 . The pharmaceutical composition of claim 1 , comprising 7-methanesulfonylheptanenitrile.
3 . The pharmaceutical composition of claim 2 , wherein the compound has at least 90% (w/w) purity, and the composition is in a topical form of gels, creams, lotions, ointments, or patches.
4 . The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethyl ether, caprylic/capric triglyceride, octisalate, silicone fluid, squalene, and sunflower oil.
5 . The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethyl ether.
6 . The pharmaceutical composition of claim 5 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine.
7 . The pharmaceutical composition according to claim 2 , wherein the compound has at least 90% (w/w) purity, and the composition is in an oral form of tablets or capsules.
8 . The pharmaceutical composition of claim 1 , comprising 5-methanesulfonylpentanenitrile.
9 . The pharmaceutical composition of claim 8 , wherein the compound has at least 90% (w/w) purity, and the composition is in a topical form of gels, creams, lotions, ointments, or patches.
10 . The pharmaceutical composition of claim 9 , wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethyl ether, caprylic/capric triglyceride, octisalate, silicone fluid, squalene, and sunflower oil.
11 . The pharmaceutical composition of claim 10 , wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethyl ether.
12 . The pharmaceutical composition of claim 11 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine.
13 . The pharmaceutical composition according to claim 9 , wherein the compound has at least 90% (w/w) purity, and the composition is in an oral form of tablets or capsules.